Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDH1 | P12830 | 1/20 | 0.63 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.63 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892967 | 0.86 | CDH1 (0.82) | CDH1CTNNB1TCF7L2NPC1RAB9A | |
| SCHEMBL11275129 | 0.84 | CDH1 (0.61) | CDH1CTNNB1TCF7L2NPC1RAB9A | |
| SCHEMBL892678 | 0.84 | ALDH1A1 (0.73) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15437038 | 0.80 | TP53 (0.59) | CDH1CTNNB1TCF7L2SMN1; SMN2TP53 | |
| SCHEMBL24198778 | 0.80 | SMN1; SMN2 (0.59) | CDH1CTNNB1TCF7L2NPC1RAB9A | |
| SCHEMBL18257901 | 0.78 | CDH1 (0.70) | CDH1CTNNB1TCF7L2NPC1RAB9A | |
| SCHEMBL20149361 | 0.78 | CDH1 (1.00) | CDH1CTNNB1TCF7L2NPC1RAB9A | |
| SCHEMBL9057987 | 0.77 | TP53 (0.65) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL1686347 | 0.77 | POLB (0.66) | CDH1CTNNB1TCF7L2SMN1; SMN2TP53 | |
| SCHEMBL19000598 | 0.76 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115508-A1 | PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-04-28 | — | — | US | disclosed |
| EP-3003317-A2 | PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS | University Of Rochester (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014197591-A2 | PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS | UNIVERSITY OF ROCHESTER (US) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115508-A1 | PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS | CYP3A43, POR, CYP3A4 | CDH1 4484/4885CTNNB1 3915/4885TCF7L2 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.